Enovis (NYSE:ENOV) versus electroCore (NASDAQ:ECOR) Financial Contrast

Enovis (NYSE:ENOV) and electroCore (NASDAQ:ECOR) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, profitability, valuation and risk.

Profitability

This table compares Enovis and electroCore’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Enovis	-47.96%	12.03%	4.91%
electroCore	-39.96%	N/A	-81.35%

Earnings and Valuation

This table compares Enovis and electroCore”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enovis	$2.25 billion	0.45	-$1.18 billion	($19.26)	-0.91
electroCore	$36.97 million	2.32	-$13.97 million	($1.66)	-5.73

electroCore has lower revenue, but higher earnings than Enovis. electroCore is trading at a lower price-to-earnings ratio than Enovis, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and price targets for Enovis and electroCore, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enovis	1	1	10	0	2.75
electroCore	1	1	1	0	2.00

Enovis currently has a consensus price target of $39.50, indicating a potential upside of 126.54%. electroCore has a consensus price target of $18.00, indicating a potential upside of 89.27%. Given Enovis’ stronger consensus rating and higher possible upside, analysts clearly believe Enovis is more favorable than electroCore.

Risk & Volatility

Enovis has a beta of 1.37, meaning that its stock price is 37% more volatile than the S&P 500. Comparatively, electroCore has a beta of 1.05, meaning that its stock price is 5% more volatile than the S&P 500.

Insider and Institutional Ownership

98.5% of Enovis shares are owned by institutional investors. Comparatively, 26.7% of electroCore shares are owned by institutional investors. 2.9% of Enovis shares are owned by insiders. Comparatively, 7.8% of electroCore shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Enovis beats electroCore on 9 of the 14 factors compared between the two stocks.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments. Its Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. The company's Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. The company distributes its products through independent distributors and directly under the ESAB and DJO brands. Enovis Corporation was formerly known as Colfax Corporation. The company was founded in 1995 and is headquartered in Wilmington, Delaware.

About electroCore

electroCore, Inc., a commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally. The company is developing gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania. It also develops Truvaga for the support of general health and wellbeing; and TAC-STIM for human performance. In addition, the company offers gammacore Sapphire, a portable, reusable, rechargeable, and reloadable prescription medical device for various primary headache conditions. electroCore, Inc. was incorporated in 2005 and is headquartered in Rockaway, New Jersey.